Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx Import Bill Endorsed By Kessler; Beats “Uncontrolled Risk”

Executive Summary

Legislation to create a regulated system for importing drugs would be safer than the current system of unregulated personal importation, former FDA Commissioner David Kessler told a Senate Health Committee hearing April 19

You may also be interested in...



Drug Importation Is “Diminishing,” NACDS CEO Fuller Says

Anecdotal evidence suggests that drug importation from Canada is declining, National Association of Chain Drug Stores CEO Craig Fuller said May 2

Drug Importation Is “Diminishing,” NACDS CEO Fuller Says

Anecdotal evidence suggests that drug importation from Canada is declining, National Association of Chain Drug Stores CEO Craig Fuller said May 2

Reimportation Bill From Dorgan/Snowe Includes User Fees To Fund Oversight

A reimportation bill reintroduced by Sens. Byron Dorgan (D-N.D.) and Olympia Snowe (R-Maine) includes user fees for importers and foreign exporters to fund FDA's safety oversight

Related Content

Topics

UsernamePublicRestriction

Register

PS045720

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel